Top line results are imminent, and the CEO is still buying stock.
H.C. Wainwright initiates coverage on CEL-SCI to Buy.
The American Cancer Society just published a new report and says oral cancer death rates have increased over the past decade.
We believe that the trial has a high probability of being successful and that the stock is deeply undervalued.
CEL-SCI Corp.'s (NYSEMKT:CVM) Phase III clinical trial of Multikine is about to end soon. We believe, through the due diligence that we have carried out, there is very little risk the primary endpoint